Go Pro
→ Control 100 shares without spending thousands of dollars (From Base Camp Trading) (Ad)tc pixel
NASDAQ:FBLG

FibroBiologics Q2 2026 Earnings Report

FibroBiologics logo
$0.71 -0.02 (-3.20%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-1.40%)
As of 07/24/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

FibroBiologics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.93
Beat/Miss
N/A
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q2 2026
Date
7/30/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

FibroBiologics Earnings Headlines

FibroBiologics (FBLG) Expected to Release Earnings on Thursday
July 23 at 2:40 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30915832
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
July 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/fibrobiologics-appoints-kathleen-kate-rubins-phd-to-board-of-directors-302821408.html
Universal Basic Income ALREADY exists
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal basic income. His Patriot Income Plan - funded by 14 partnerships controlling America's critical oil and gas infrastructure - already pays 10% a year with 42 payouts annually. Some investors are already collecting $4,800 a month. One has built income up to $25,000 a month. These partnerships have averaged 20% annual gains since 2020, with no U.S. tax dollars involved. The next payout drops in days.tc pixel
July 26 at 1:00 AM  |  Freedom Financial (Ad)
FibroBiologics, Inc.: FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/68963306-fibrobiologics-inc-fibrobiologics-completes-manufacturing-of-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial-008.htm
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/fibrobiologics-completes-manufacturing-of-third-batch-of-cywc628-drug-product-for-phase-12-diabetic-foot-ulcer-clinical-trial-302819414.html
FibroBiologics Secures New Private Placement Financing
July 1, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3064417/fibrobiologics-secures-new-private-placement-financing/
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile
Earnings Tools